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SudanABSTRACT
Objective: To determine the prevalence and antimicrobial resistance rates of nosocomial
pathogens isolated from cancer patients and hospital environments.
Methods: A descriptive cross-sectional study was conducted between December 2010 to
May 2013 at Radiation and Isotopes Centre of Khartoum, Sudan. A total of 1503 samples
(505 clinical and 998 environmental) were examined. Isolates were identiﬁed, and their
antimicrobial susceptibility was determined using standard laboratory procedures.
Results: Out of 505 clinical samples, nosocomial pathogens were found as 48.1%.
Among hospital environment samples, bacterial contaminants were detected in 29.7% of
samples. The main microorganisms recovered from cancer patients were Proteus spp.
(23.5%), Escherichia coli (22.2%), Pseudomonas aeruginosa (P. aeruginosa) (21.0%)
and Staphylococcus aureus (20.2%). The most frequent isolates from hospital environ-
ments were Bacillus spp. (50.0%), Staphylococcus aureus (14.2%) and P. aeruginosa
(11.5%). The proportions of resistance among Gram-negative pathogens from cancer
patients were high for ampicillin, cefotaxime, ceftazidime and ceftriaxone. Moderate
resistance rates were recorded to ciproﬂoxacin, such as 51.0% for P. aeruginosa, 21.7%
for Klebsiella pneumoniae and 55.5% for Escherichia coli. Except Klebsiella, there were
no signiﬁcant differences (P  0.05) of resistance rates between Gram-negative isolates
from cancer patients to those from the hospital environments. The proportions of
extended-spectrum b-lactamase producing isolates from cancer patients were not differ
signiﬁcantly (P = 0.763) from those collected from the hospital environments (49.2%; 91/
185 vs. 47%; 32/68).
Conclusions: The prevalence of nosocomial infection among cancer patients was high
(48.1%) with the increasing of antimicrobial resistance rates. Hospital environments are
potential reservoirs for nosocomial infections, which calls for intervention program to
reduce environmental transmission of pathogens.1. Introduction
Nosocomial infection is one of the most common life-
threatening complications of immunocompromised hospitalized
patients [1,2]. Cancer patients are more susceptible to hospital
acquired infections due to their compromised immune system,
the use of invasive technologies and they being subjected tosurgical operations and chemotherapy [3,4]. Bacterial infection
among cancer patients is continuing to emerge as particularly
destructive complications of cancer treatment [2,5]. This
infection among cancer patients could happen either as
endogenously from normal ﬂora on the skin or on the
operative site or exogenously from the air, hospital staff,
inanimate environment and medical equipments [6,7]. Patients
with cancer are highly susceptible to almost any type of
bacterial infection [3]. The colonization of the potentially
pathogenic microorganisms on the various inanimate surfaces
presents in a clinical setup has been reported as a potential
vehicle for the transmission of nosocomial pathogens [6,7].ess article under the CC BY-NC-ND
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commonly used antibacterial agents, has created a potential
public health problem, particularly among cancer patients [2,5].
The increasing of antimicrobial resistance rates among
bacterial pathogens isolated from cancer patients and hospital
environments are posing new challenges [5]. Many studies
have been conducted to determine the prevalence of
nosocomial infections among cancer patients in developed
countries and developing countries [8–10]. In Sudan, no current
data available documented nosocomial infections among
cancer patients. Therefore, the aim of the present study was to
determine the incidence and antimicrobial resistance of
nosocomial pathogens isolated from cancer patients who
admitted to the Radiation and Isotopes Centre of Khartoum in
Sudan. In addition, the study also analyzed the distribution of
pathogens that isolated from hospital environments.
2. Materials and methods
2.1. Study design and population
This descriptive cross-sectional hospital based study was con-
ducted during the period from December 2010 to May 2013 in
Radiation and Isotopes Centre of Khartoum, Khartoum state,
Sudan. The Radiation and Isotopes Centre of Khartoum is one of
themain oncology centers in Sudan, providing treatment for cancer
patients with radiotherapy, chemotherapy and hormonal therapy
[11]. All cancer patients who attended Radiation and Isotopes
Centre of Khartoum were enrolled in the study. Each patient
with no proven evidence of infection at the time of admission,
but developed signs of infection after at least two days of
hospitalization was included in the study. Patients with proven
evidence of infection at the time of admission to the hospital
were excluded from the study. The study was approved by the
Research Committee of the Faculty of Medical Laboratory
Sciences, University of Khartoum. All patients included in this
study were consented verbally before collection of samples.
2.2. Collection of samples
Clinical samples of urine (n = 325), wound pus (n = 130),
blood (n = 20) and sputum (n = 30) were collected from cancer
patients for the investigations of pathogenic microorganism
following standard laboratory procedures [12]. Hospital
specimens were collected from different moist environments,
including infrastructures (n = 551), furniture (n = 232),
surgical equipments (n = 123), laboratories (n = 68), kitchens
(n = 24) using sterile moist cotton swabs. All the collected
specimens were properly labeled and the data were collected
via a questionnaire form.
2.3. Isolation and identiﬁcation of bacterial species
For possible isolation of bacterial pathogens, each specimen
(clinical or environmental) were inoculated onto blood agar
(HiMedia, India) and MacConkey agar (HiMedia, India) plates.
Then all cultured plates were incubated aerobically at 37 C for
24 h. Blood samples were inoculated onto brain heart infusion
broth and incubated at 37 C for a period of 7–14 days. Each
bacterial isolate was identiﬁed on the bases colonial
morphology, Gram staining and required biochemical tests
following standard laboratory methods [12].2.4. Antimicrobial susceptibility testing
Antimicrobial susceptibility testing was performed using
Kirby–Bauer disc diffusion technique on Mueller-Hinton agar
medium (HiMedia, India) as recommended by the Clinical and
Laboratory Standards Institute [13]. Isolates were tested for their
susceptibility against different antimicrobial agents, including:
amikacin (30 mg), ampicillin (10 mg), cefotaxime (30 mg),
ceftazidime (30 mg), ceftriaxone (30 mg), ciproﬂoxacin (5 mg),
gentamicin (10 mg), meropenem (10 mg) (HiMedia, India). The
strain of Escherichia coli ATCC 25922 (E. coli) was used as
control, and was examined each time when susceptibility
testing was carried out. The test result was only validated in
cases where inhibition zone diameters of the control strain
within the performance range in accordance to the Clinical
and Laboratory Standards Institute criteria [13].
2.5. Screening of extended-spectrum b-lactamase
(ESBL) production
Gram-negative isolates recovered from cancer patients and
hospital environments were screened for ESBL production by
the double disc synergy test as described by Jarlier et al. [14].
All the isolates showed the resistance to third generation
cephalosporin were examined for ESBL production. A disc
containing amoxicillin/clavulanic acid (30 mg) was placed in
the centre of the Mueller-Hinton agar plate, and discs contain-
ing ceftriaxone (30 mg), cefotaxime (30 mg) and ceftazidime
(30 mg) were placed 30 mm distance from the disc of
amoxicillin/clavulanic acid. A clear extension of the edge of the
inhibition zone of third generation cephalosporin towards
amoxicillin/clavulanic acid disc is interpreted as positive for
ESBL production. Control strains of Staphylococcus aureus
ATCC 25923 (S. aureus), E. coli and Pseudomonas aeruginosa
ATCC 27853 (P. aeruginosa) were run at the same time on
separate plates using the same turbidity as in the test organism
to evaluate the conditions of the test and the potency of the
discs.
2.6. Statistical analysis
The data obtained was coded and entered into the SPSS,
version 16.0. The Chi-square test was used to test for the sig-
niﬁcant differences between the variables. P < 0.05 was
considered as statistically signiﬁcant.
3. Results
A total of 505 clinical samples collected from cancer patients
(443 adults and 62 children) and 998 swab samples obtained
from hospital environments were screened for the presence of
bacterial pathogens. Out of the 505 clinical samples, pathogenic
bacteria were detected in 48.1% (243). Of the 243 clinical iso-
lates, 203 were recovered from adult patients and 40 from
children. The majority of the isolates were from urine (n = 117),
and wound pus (n = 113), with low frequency of the isolates
from sputum (n = 12) and blood (n = 1) samples.
Overall the 998 swab specimens collected from hospital
environments, 296 (29.7%) were yielded different bacterial
species. As shown in Table 1, the most frequent microorganisms
among cancer patients were Proteus spp. (23.5%), E. coli
Table 1
Frequency of different bacterial species isolated from cancer patients and
hospital environments.
Bacterial isolate Cancer patients Hospital
environment
(%)
Adult Child Total (%)
E. coli 46 8 54 (22.2) 2 (0.7)
P. aeruginosa 46 5 51 (21.0) 34 (11.5)
Proteus species 48 9 57 (23.5) 10 (3.4)
S. aureus 38 11 49 (20.2) 42 (14.2)
K. pneumoniae 18 5 23 (9.4) 22 (7.4)
Streptococcus pneumonia 7 2 9 (3.7) –
Bacillus species – – – 148 (50.0)
Coagulase negative
Staphylococcus
– – – 32 (10.8)
Micrococcus – – – 6 (2.0)
Total 203 40 243 296
K. pneumoniae: Klebsiella pneumoniae.
Table 3
Comparison of the proportion of ESBL producing Gram-negative rods
recovered from cancer patients to that collected from hospital environ-
ments. n (%).
Bacterial isolate Cancer patients
isolates
(n = 185)
Hospital environment
isolates
(n = 68)
K. pneumoniae 30 (32.9) 12 (37.5)
E. coli 23 (25.3)* 0 (0.0)*
P. aeruginosa 21 (23.1)* 17 (53.1)*
Proteus mirabilis 14 (15.4) 2 (6.3)
Proteus vulgaris 3 (3.3) 1 (3.1)
Total 91 (49.2) 32 (47.0)
*: Indicate signiﬁcant differences (P < 0.05) in the proportion of ESBL
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negative bacteria were more frequently isolates from cancer
patients than Gram-positive bacteria (76.1%; 185/243 vs.
23.9%; 58/243). Of the hospital environment isolates, Bacillus
spp. were the common isolates (50%; 148/296) followed by
S. aureus (14.2%; 42/296) and P. aeruginosa (11.5%; 34/296)
(Table 1).
3.1. Antimicrobial susceptibility testing of the isolates
Table 2 summarizes the antimicrobial resistance patterns of
Gram-negative bacilli isolated from cancer patients in com-
parison to the hospital environment isolates. There were no
signiﬁcant differences (P  0.05) of resistance rates to the most
tested antimicrobial agents between isolates (Proteus and
Pseudomonas) from cancer patients to those from the hospital
environments. On the other hand, both clinical and environ-
mental isolates showed signiﬁcant difference of resistance rates
to four antimicrobials, including, ampicillin (P = 0.020 for
Proteus), ciproﬂoxacin (P = 0.001 for Proteus), gentamicin
(P = 0.002 for Proteus; P = 0.018 for Pseudomonas), ceftazi-
dime (P = 0.024 for Pseudomonas). Among K. pneumoniae
isolates, signiﬁcant differences of resistance rates were recor-
ded as follow (cancer patients isolates vs. hospital environment
isolates) to: amikacin (0.0% vs. 27.3%; P = 0.007), ampicillinTable 2
Comparison of antimicrobial resistance rates of Gram-negative nosocomial p
Antimicrobial agent Proteus spp. P. aerugeno
Patient
(n = 57)
Hospital
environment
(n = 10)
Patient
(n = 51)
Ho
envi
(n
Amikacin 43.8 30.0 13.7
Ampicillin 63.1* 100.0* 100.0 1
Cefotaxime 100.0 100.0 94.1 1
Ceftazidime 86.0 100.0 86.3* 1
Ceftriaxone 96.5 100.0 96.1 1
Ciproﬂoxacin 96.5* 0.0* 51.0
Gentamicin 52.6* 0.0* 49.0*
Meropenem 45.6 33.3 23.5*
*: Indicate signiﬁcant differences (P < 0.05) in antimicrobial resistance rate(82.6% vs. 100.0%; P = 0.04), ceftazidime (69.6% vs. 100%,
P = 0.004), ciproﬂoxacin (21.7% vs. 54.5%; P = 0.023),
gentamicin (0.0% vs. 45.4%; P < 0.001). In general,
K. pneumoniae isolated from hospital environment were found
to be more resistant than that isolated from cancer patients to
the most commonly selected antimicrobial agents.
The proportions of resistance rates among Gram-negative
isolates from cancer patients were high for ampicillin such as
63.1% for Proteus spp., 82.8% for K. pneumoniae, 88.9% for
E. coli and 100.0% for P. aerugenosa. In addition, high resis-
tance rates to ceftriaxone among isolates were recorded, such as
92.6% for E. coli, 96.1% for P. aeruginosa, 96.5% for Proteus
spp., and 100.0% for K. pneumoniae. Similar high resistance
rates among Gram-negatives isolates were observed for cefo-
taxime and ceftazidime. On the other hand, moderate resistance
rates were recorded to ciproﬂoxacin, such as 51.0% for
P. aeruginosa, 21.7% for K. pneumoniae, 55.5% for E. coli.
Furthermore, moderate resistance rates were also recorded for
amikacin, gentamicin and meropenem (Table 2).
3.2. Detection of ESBLs production
Table 3 summarizes the proportions of ESBL producing
Gram-negative microorganisms recovered from cancer patients
and hospital environments. Overall the isolates, the proportions
of ESBL producing isolates from cancer patients did not differ
signiﬁcantly (P = 0.763) from those collected from the hospital
environment (49.2%; 91/185 vs. 47.0%; 32/68).athogens recovered from cancer patients and hospital environment. %.
sa K. pneumoniae E. coli
spital
ronment
= 34)
Patient
(n = 23)
Hospital
environment
(n = 22)
Patient
(n = 54)
Hospital
environment
(n = 2)
23.5 0.0* 27.3* 27.8 0.0
00.0 82.6* 100.0* 88.9 50.0
00.0 91.3 100.0 100.0 100.0
00.0* 69.6* 100.0* 81.5 100.0
00.0 100.0 100.0 92.6 100.0
70.1 21.7* 54.5* 55.5 0.0
23.5* 0.0* 45.4* 0.0 0.0
70.1* 56.5 68.2 24.1 0.0
s between hospital and clinical isolates.
producing isolates from cancer patients and hospital environments.
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Cancer patients are known to be susceptible to various
nosocomial infections due to the negative effect of therapeutic
practices on their immune system [1,15]. In the present study, we
have analyzed the distribution and antimicrobial resistance of
nosocomial pathogens isolated from cancer patients admitted
to the Radiation and Isotopes Centre in Khartoum, Sudan. In
addition, we estimated the frequency of bacterial pathogens
isolated from hospital environments. We found that the
incidence of nosocomial infections among cancer patients was
48.1%. In a study carried out in an oncology center, 12.0% of
the patients developed nosocomial infections [16]. Another
study found that 27.6% of adult cancer patients had bacterial
bloodstream infections [17]. In this report, the predominant
microorganisms causing nosocomial infections among cancer
patients were Proteus spp. (23.5%), E. coli (22.2%),
P. aeruginosa (21%) and S. aureus (20.2%). In Egypt, as a
neighboring country, the most frequent isolates among patients
with leukemia and solid tumors were K. pneumoniae (31.2%)
followed by E. coli (22.2%) [1]. Our ﬁndings revealed that
Gram-negative bacteria were signiﬁcantly more predominant
isolates from cancer patients than Gram-positive bacteria (76.1%
vs. 23.9%; P < 0.001). Similar ﬁndings have been documented
by others [18]. Recently, Trecarichi and Tumbarello [9] reported
that the rate of Gram-negative bacteria recovery ranged from
24.7% to 75.8% in cancer patient cohorts. E. coli represented the
most common species (mean frequency of isolation 32.1%)
among the Gram-negatives, followed by P. aeruginosa (mean
frequency of isolation 20.1%) [9]. Saghir et al. [10] noticed that
Gram-negative bacteria were found associated with blood-
stream infections in cancer patients. P. aeruginosa (38%) had
been the most frequent bacterial isolates, followed by E. coli
(25%), K. pneumoniae (20%), Proteus vulgaris (10%) and
Shigella (8%) [10]. The epidemiology of bacterial infections
among cancer patients showing a shift in the prevalence from
Gram-positive to Gram-negative bacteria have been docu-
mented [9,19]. In contrary, current data indicate that Gram-
positive microorganisms are predominant in patients with fe-
ver, neutropenia and hematological neoplasias followed by
Gram-negatives like E. coli [20]. These ﬁndings indicated needs
for evaluation of the local distribution of nosocomial
pathogens and their susceptibility patterns and prompt
initiation of effective antimicrobial treatment for severe
bacterial infection in cancer patients [9].
The increasing rates of drug resistance among Gram-negative
and Gram-positive pathogens are being documented in many
hospitals, including cancer treatment centers [9]. In this study,
Gram-negative bacterium revealed high resistance rates to b-
lactams and cephalosporins groups. On the other hand, moderate
resistance rates were recorded to ciproﬂoxacin, such as 51.0%
for P. aeruginosa, 21.7% for K. pneumonia and 55.5% for
E. coli. Moreover, moderate resistance rates also were recorded
for aminoglycoside agent. Likewise, high resistant rates among
Gram-negative rods to most of the commonly used antimicrobial
groups have been determined by others [21,22]. Worldwide
studies have been attributed to the increasing rates of
cephalosporins among Enterobacteriaceae member due to b-
lactamase activity [10,21,23].
In the hospital situations, the threat of contamination with
potential pathogens is a great concern [7]. Our study showed that
about 30% of the hospital environment samples werecontaminated with different bacterial species. Furthermore, we
found that the leading nosocomial isolates were S. aureus
followed by P. aeruginosa, and K. pneuomoneae. In
comparison of Gram-negative isolates from cancer patients to
those from hospital environments in terms of resistance rates and
ESBL production, there were almost no signiﬁcant differences
(P  0.05) of resistance rates between both isolates. Exception-
ally, K. pneumoniae isolated from cancer patients revealed a
signiﬁcant difference to those from the hospital environments of a
resistance rate from amikacin, ampicillin, ceftazidime, cipro-
ﬂoxacin and gentamicin. Our data suggested that hospital
contaminant environments could be a mediator of cross trans-
mission of nosocomial pathogens. Many of the nosocomial in-
fections are acquired during the medical procedures, particularly
with cancer patients [2]. In addition, other studies have reported
the possibility of cross transmission of nosocomial bacterium
from hospital devices and instruments [24,25]. Furthermore,
hands and instruments used by health care workers have been
recognized as vectors for the nosocomial transmission of
microorganisms [24]. The inanimate objects and medical tools
such as stethoscopes, ear thermometers, bronchoscopes, bedrails
and bedside tables, bath basins or plumbing components in the
patient's environment can harbor microorganisms [6,7,25]. The
transmissions of nosocomial pathogens by electronic devices
such as personal digital assistants, cell phone, handheld
computers have been previously reported [26]. Therefore, the
daily infection management that includes maintenance of hand
hygiene, disinfection and sterilization of objects in the patients'
environments to eliminate and reduce nosocomial pathogens
should be implemented [6,25,27].
In conclusion, we found that the prevalence of nosocomial
pathogens with cancer patients was high (48.1%). Gram-
negative bacteria were the common cause of nosocomial infec-
tion among cancer patients. Antimicrobial resistance rates of
nosocomial pathogens among this high-risk group were elevated
and are becoming a clinical challenge. Hospital environment is a
potential reservoir of different bacterial species which could be a
source of transmission of nosocomial infection. Our ﬁndings
highlight the need of intervention program to develop the
cleaning methods as a way of reducing environmental trans-
mission of pathogenic microorganisms. In addition, molecular
epidemiological investigations of the clonal spread of speciﬁc
pathogens should be included in infection control practices.
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